Bristol Myers Squibb Reports H1 2023 CAR-T Therapy Revenue of $450 Million (Approx. RMB 3.23 Billion)

On July 27, 2023, Bristol-Myers Squibb (BMS) announced its Q2 2023 financial report: revenue reached $11.226 billion, compared to $11.887 billion in the prior period and $11.81 billion expected, representing a 4.94% shortfall from market expectations; earnings per share were $1.75, compared to $1.93 in the prior period and $1.98 expected, representing an 11.62% shortfall from market expectations. Revenue from mature products (In-Line) was $8.6 billion, while revenue from newly launched products (New Product Portfolio) was approximately $900 million.

Among them, two products from BMSCAR-TTherapies Abecma and Breyanzi Q2 Revenue Totals $232 Million.

In addition, Abecma's sales in Q1 2023 were $147 million, and Breyanzi's sales in Q1 2023 were $71 million.Two CAR-T therapies generated a total revenue of $450 million (approximately RMB 3.227 billion) in H1 2023In addition, Abecma and Breyanzi generated revenues of $388 million and $182 million respectively in 2022.

（1）Breyanzi

Time to market: February 2021FDAApproved for marketing.

Indications: Relapsed or Refractory (R/R) Large B-CellLymphoma（LBCL）。

Note: Breyanzi is a lentivirus-based ex vivo gene therapy, and it is the fourth CAR-T therapy approved for marketing globally, targeting CD19. The approval of Breyanzi marks Bristol-Myers Squibb's advancement in the field of cell therapy.ImmunityA milestone in the treatment field, the drug was acquired by Bristol-Myers Squibb when it purchased Celgene for $74 billion in 2019.

（2）Abecma

Time to market: Approved for marketing by the FDA in March 2021.

Indications: Relapsed or refractory multiple myeloma.

Note: Abecma is a lentivirus-based ex vivo gene therapy, the world's first CAR-T cell therapy targeting BCMA, and the fifth CAR-T therapy approved by the FDA. The drug works by using lentivirus-mediated gene modification to express chimeric BCMA receptors on the patient’s autologous T cells ex vivo. Before infusion of this cellular gene therapy, patients are pretreated with two compounds, cyclophosphamide and fludarabine, to deplete unmodified T cells in the body. Subsequently, the modified T cells are reinfused into the patient, where they seek out and destroy cancer cells expressing BCMA.

Bristol-Myers Squibb (BMS) Company Profile: Bristol-Myers Squibb Company is a global, research-based diversified enterprise engaged in pharmaceuticals, healthcare, and personal care products, primarily focusing on the discovery, development, licensing, manufacturing, marketing, distribution, and sales of biopharmaceutical products. The company was founded in August 1933 and is headquartered in New York City, New York.